Artificial Intelligence Approaches for Signal Detection and Benefit–Risk Assessment of Approved Alzheimer's Disease Drugs in Post-Marketing Surveillance

Shaik Asha Begum*[1], Kishore Gangolu[2], Shaik Muskan[3], TM. Keerthi[4], G. Sai Niranjan[4], P. Jagadeesh Naidu[4], Chandraja Devireddy[5], Pallapothu Charishma Bharathi[6]

[1]Department of Regulatory Affairs, KVSR Sidhartha College of Pharmaceutical Sciences, Vijayawada, Andra Pradesh, India-520010

[2] Masters of Public health, Buckinghamshire New University

[3] Pharm D, Nirmala College of Pharmacy, Atmakur, Mangalagiri.

[4] M.Pharmacy (Regulatory Affairs), KVSR Sidhartha College of Pharmaceutical Sciences, Vijayawada, Andra Pradesh, India-520010

[5]Pharm D, KVSR Sidhartha College of Pharmaceutical Sciences, Vijayawada, Andra Pradesh, India-520010

[6]B.Pharmacy, KVSR Sidhartha College of Pharmaceutical Sciences, Vijayawada, Andra Pradesh, India-520010

Corresponding Author: Shaik Asha Begum

Email: sk.asha86@gmail.com

Mobile No: 9014016100

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and a leading cause of dementia worldwide, posing significant clinical, economic, and public health challenges. In recent years, several novel therapies have been approved for the management of Alzheimer's disease; however, their long-term safety profiles continue to evolve after market authorization. Post-marketing pharmacovigilance plays a critical role in identifying rare, delayed, and previously unrecognized adverse drug reactions that may not be detected during clinical trials. Artificial Intelligence (AI) has emerged as a powerful tool for enhancing pharmacovigilance activities through automated data analysis, signal detection, and risk assessment.

This study explores the application of AI-based approaches for detecting emerging safety signals and evaluating the benefit–risk profile of approved Alzheimer's disease drugs using post-marketing surveillance data. Machine learning algorithms, natural language processing techniques, and data-mining methods can efficiently analyze large volumes of adverse event reports obtained from pharmacovigilance databases, electronic health records, and real-world evidence sources. AI-driven models facilitate early identification of potential safety concerns, support regulatory decision-making, and contribute to continuous benefit–risk monitoring throughout the product lifecycle.

The integration of AI into pharmacovigilance systems offers opportunities to improve signal detection accuracy, reduce manual workload, and enhance patient safety. However, challenges related to data quality, model transparency, regulatory acceptance, and ethical considerations remain important. This paper discusses the role of AI in modern pharmacovigilance and highlights its potential to strengthen post-marketing safety surveillance and benefit–risk assessment of Alzheimer's disease therapeutics.

Keywords

Artificial Intelligence; Alzheimer's Disease; Pharmacovigilance; Signal Detection; Post-Marketing Surveillance; Benefit–Risk Assessment; Machine Learning; Drug Safety; Regulatory Affairs; Real-World Evidence

How to cite this article: Begum SA, Gangolu K, Muskan S, Keerthi TM, Niranjan GS, Naidu PJ, Devireddy C, Bharathi PC. Artificial Intelligence Approaches for Signal Detection and Benefit–Risk Assessment of Approved Alzheimer's Disease Drugs in Post-Marketing Surveillance. Int J Drug Deliv Technol. 2026;16(64s):1059-1068. DOI: 10.25258/ijddt.16.64s.103

1. Introduction

Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder characterized by gradual deterioration of memory, cognition, behavior, and the ability to perform daily activities. It is the most common cause of dementia worldwide and represents a major public health challenge due to the increasing aging population. According to global health estimates, millions of individuals are currently living with Alzheimer's disease, and this number is expected to rise substantially in the coming decades, placing significant social, economic, and healthcare burdens on patients, caregivers, and healthcare systems.

The pathological hallmarks of Alzheimer's disease include the accumulation of extracellular amyloid-beta plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, neuronal loss, and progressive brain atrophy. These pathological changes begin years before the onset of clinical symptoms, making early diagnosis and effective therapeutic intervention particularly challenging. Over the years, several pharmacological therapies have been approved for

the management of Alzheimer's disease, including cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, as well as the N-methyl-D-aspartate (NMDA) receptor antagonist memantine. More recently, disease-modifying therapies targeting amyloid-beta pathology have been introduced, representing a significant advancement in Alzheimer's disease treatment.

While clinical trials provide essential evidence regarding the safety and efficacy of new therapies, they are conducted under controlled conditions and involve relatively limited patient populations. Consequently, rare adverse drug reactions, long-term safety concerns, and effects in special populations may not become apparent until a drug is used extensively in real-world clinical practice. This highlights the critical importance of post-marketing surveillance and pharmacovigilance activities in ensuring the continued safety of approved Alzheimer's disease therapies throughout their lifecycle.

Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Regulatory authorities worldwide, including the U.S. Food and Drug Administration, European Medicines Agency, and World Health Organization, rely on pharmacovigilance systems to monitor the safety of marketed medicines. These systems collect large volumes of adverse event reports from healthcare professionals, patients, pharmaceutical companies, and healthcare databases. However, the rapidly increasing volume and complexity of safety data present significant challenges for traditional pharmacovigilance methods, which often depend heavily on manual review and expert assessment.

Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize pharmacovigilance and regulatory science. AI encompasses a range of computational techniques, including machine learning, deep learning, natural language processing, and predictive analytics, that enable computers to learn from data, recognize patterns, and make informed predictions. These technologies can process vast amounts of structured and unstructured data far more efficiently than conventional analytical approaches.

In the context of post-marketing surveillance, AI can facilitate the early detection of emerging safety signals by analyzing adverse event reports, electronic health records, medical literature, patient registries, and real-world evidence databases. Machine learning algorithms can identify previously unrecognized associations between drugs and adverse events, while natural language processing techniques can extract valuable safety information from narrative reports and clinical documents. Such capabilities enable more proactive identification of potential safety concerns and support timely regulatory interventions.

Beyond signal detection, AI can also contribute to benefit–risk assessment, a fundamental component of regulatory decision-making. Benefit–risk assessment involves evaluating whether the therapeutic benefits of a medicine outweigh its potential risks. As new safety information emerges during post-marketing use, regulatory authorities must continuously reassess the overall benefit–risk profile of approved therapies. AI-driven analytical models can integrate data from multiple sources to provide comprehensive insights into treatment effectiveness, safety trends, and patient outcomes, thereby supporting evidence-based regulatory decisions.

Despite its considerable promise, the implementation of AI in pharmacovigilance is associated with several challenges, including data quality issues, algorithm transparency, model validation requirements, ethical considerations, and regulatory acceptance. Addressing these challenges is essential to ensure the reliability, reproducibility, and trustworthiness of AI-generated findings within regulatory environments.

This paper explores the application of Artificial Intelligence approaches for signal detection and benefit–risk assessment of approved Alzheimer's disease therapies using post-marketing surveillance data. It examines the role of AI in enhancing pharmacovigilance activities, discusses current methodologies and regulatory considerations, and highlights future opportunities for integrating advanced computational technologies into drug safety monitoring and regulatory decision-making processes.

2. Alzheimer's Disease Therapeutics and Regulatory Challenges

Alzheimer's disease (AD) management has evolved significantly over the past three decades with the approval of symptomatic and disease-modifying therapies. Currently approved treatments include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which improve cognitive function by increasing acetylcholine levels in the brain. Memantine, an NMDA receptor antagonist, is prescribed for moderate-to-severe Alzheimer's disease to reduce excitotoxic neuronal damage. More recently, anti-amyloid monoclonal antibodies have emerged as disease-modifying therapies aimed at reducing amyloid plaque burden and slowing disease progression.

Despite demonstrated clinical benefits, these therapies are associated with adverse events ranging from mild gastrointestinal disturbances to serious neurological complications such as amyloid-related imaging abnormalities (ARIA), cerebral edema, and intracerebral hemorrhage. Since pre-approval clinical trials often involve limited patient populations and controlled study conditions, certain rare or delayed adverse drug reactions may only become apparent after widespread clinical use.

Regulatory agencies continuously monitor approved Alzheimer's therapies to ensure that their benefits

continue to outweigh potential risks. This requires comprehensive post-marketing surveillance systems capable of collecting, analyzing, and interpreting large volumes of safety data from diverse sources.

Table 1. Approved Alzheimer's Disease Therapies and Key Safety Concerns

Drug/Class	Therapeutic Role	Common Safety Concerns
Donepezil	Cholinesterase inhibitor	Nausea, vomiting, bradycardia
Rivastigmine	Cholinesterase inhibitor	Gastrointestinal adverse effects
Galantamine	Cholinesterase inhibitor	Dizziness, nausea
Memantine	NMDA antagonist	Headache, confusion
Anti-amyloid antibodies	Disease modification	ARIA, cerebral edema

Figure 1. Regulatory Lifecycle Monitoring of Alzheimer's Disease Drugs



3. Pharmacovigilance and Post-Marketing Surveillance

Pharmacovigilance refers to the science and activities associated with the detection, assessment, understanding, and prevention of adverse effects related to medicinal products. Post-marketing surveillance plays a vital role in identifying previously unknown safety concerns that may not have been detected during clinical development.

Modern pharmacovigilance systems collect information from multiple sources including spontaneous adverse event reports, electronic health records (EHRs), insurance claims databases, patient registries, scientific literature, and real-world evidence repositories. These data sources provide valuable insights into drug utilization patterns and safety outcomes across diverse patient populations.

Signal detection is one of the most important objectives of pharmacovigilance. A safety signal is defined as information suggesting a new potentially causal association between a drug and an adverse event that warrants further investigation.

Table 2. Major Sources of Post-Marketing Safety Data

Data Source	Information Obtained
FAERS	Adverse event reports
EudraVigilance	European safety reports
VigiBase	Global pharmacovigilance database
Electronic Health Records	Clinical outcomes
Patient Registries	Long-term follow-up data
Scientific Literature	Published case reports

Figure 2. Sources of Pharmacovigilance Data



4. Artificial Intelligence in Drug Safety Monitoring

The increasing volume of pharmacovigilance data presents significant analytical challenges. Artificial Intelligence (AI) offers powerful tools capable of processing and analyzing large datasets more efficiently than traditional manual approaches.

Machine learning algorithms can identify hidden patterns and associations within adverse event databases, enabling earlier recognition of emerging safety concerns. Natural Language Processing (NLP) techniques facilitate automated extraction of adverse event information from clinical narratives, literature reports, and physician notes.

Deep learning approaches further enhance pharmacovigilance by detecting complex relationships among multiple variables that may not be apparent through conventional statistical methods.

Table 3. AI Technologies Used in Pharmacovigilance

Technology	Application
Machine Learning	Signal prediction
Deep Learning	Pattern recognition
Natural Language Processing	Text mining
Neural Networks	Risk prediction
Data Mining	Signal prioritization

Figure 3. AI-Driven Pharmacovigilance Workflow



5. Methodology

This review focuses on AI-based approaches used for signal detection and benefit–risk assessment of approved Alzheimer's disease therapies. Data sources commonly utilized in pharmacovigilance research include the FDA Adverse Event Reporting System (FAERS), EudraVigilance, and the WHO

Global Individual Case Safety Report database (VigiBase).

The methodological framework involves data extraction, preprocessing, feature engineering, model training, validation, and signal evaluation. Both structured and unstructured datasets can be analyzed using AI techniques.

The primary AI methods include:

- Supervised machine learning
- Unsupervised machine learning
- Artificial neural networks
- Natural language processing
- Data mining algorithms

Table 4. AI Methodologies Applied in Safety Signal Detection

Method	Purpose
Logistic Regression	Classification
Random Forest	Signal prediction
Support Vector Machine	Pattern classification
Neural Networks	Complex relationship analysis
NLP Models	Text extraction and analysis

6. Signal Detection Approaches

Signal detection aims to identify adverse drug reactions that occur more frequently than expected. Traditional pharmacovigilance relies on disproportionality analysis methods such as Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Bayesian techniques.

AI-based signal detection approaches complement these traditional methods by analyzing multidimensional datasets and identifying complex associations among variables. Machine learning classifiers can distinguish between meaningful safety signals and background noise, thereby improving detection accuracy.

Clustering techniques can group related adverse events, while NLP models can identify emerging concerns from narrative reports and medical literature.

Table 5. Comparison of Traditional and AI-Based Signal Detection

Parameter	Traditional Methods	AI-Based Methods
Data Handling	Limited	Large-scale
Pattern Recognition	Basic	Advanced
Automation	Low	High
Predictive Capability	Moderate	High
Processing Speed	Slower	Faster

7. Benefit–Risk Assessment

Benefit–risk assessment is a critical component of regulatory decision-making. It involves evaluating whether the therapeutic benefits of a medicine outweigh its associated risks.

AI can enhance benefit–risk assessment by integrating information from clinical trials, post-marketing surveillance, patient registries, and real-world evidence. Predictive models can estimate future safety outcomes and identify patient populations that may derive the greatest therapeutic benefit.

Advanced analytics enable continuous reassessment of benefit–risk profiles throughout the product lifecycle.

8. Regulatory Implications

The incorporation of AI into pharmacovigilance has significant implications for regulatory science. AI-driven systems can support earlier identification of safety concerns, more efficient risk management, and evidence-based regulatory decision-making.

Regulatory agencies increasingly recognize the potential of AI to enhance pharmacovigilance activities. Applications include signal management, label modifications, risk minimization strategies, and post-authorization safety studies.

However, successful regulatory implementation requires transparency, reproducibility, explainability, and robust model validation.

Table 6. Regulatory Applications of AI in Pharmacovigilance

Regulatory Activity	AI Contribution
Signal Management	Early detection
Label Updates	Evidence generation
Risk Management Plans	Risk prediction
Safety Studies	Automated monitoring
Regulatory Review	Decision support

9. Future Perspectives

The future of AI in pharmacovigilance is expected to be driven by advances in explainable AI, federated learning, generative AI, and real-world evidence integration. Explainable AI aims to improve transparency by enabling regulators and healthcare professionals to understand how models generate predictions.

Federated learning allows multiple organizations to collaborate without sharing sensitive patient data, thereby improving privacy protection while expanding analytical capabilities.

The integration of wearable devices, digital biomarkers, and real-time patient monitoring systems may further enhance safety surveillance and personalized risk assessment.

10. Conclusion

Artificial Intelligence is transforming pharmacovigilance and regulatory science by enabling efficient analysis of large-scale safety datasets and facilitating earlier detection of

emerging adverse drug reactions. In Alzheimer's disease therapeutics, where long-term safety monitoring is particularly important, AI-based approaches offer substantial advantages for signal detection and benefit–risk assessment.

Machine learning, deep learning, natural language processing, and advanced predictive analytics provide opportunities to improve the accuracy, speed, and effectiveness of post-marketing surveillance activities. While challenges related to data quality, transparency, validation, and regulatory acceptance remain, ongoing technological advancements are expected to strengthen the integration of AI into modern pharmacovigilance systems.

Ultimately, AI-driven pharmacovigilance has the potential to improve patient safety, support evidence-based regulatory decision-making, and enhance the overall lifecycle management of Alzheimer's disease therapies.

- World Health Organization. (2021). *Ethics and governance of artificial intelligence for health*. World Health Organization.
- World Health Organization. (2023). *Global report on dementia and Alzheimer's disease management*. World Health Organization.
- U.S. Food and Drug Administration. (2024). *Artificial intelligence and machine learning in drug development*. U.S. Food and Drug Administration.
- European Medicines Agency. (2023). *Guideline on good pharmacovigilance practices (GVP)*. European Medicines Agency.
- Goodfellow, I., Bengio, Y., & Aaron Courville. (2016). *Deep learning*. MIT Press.
- Yann LeCun, Yoshua Bengio, & Geoffrey Hinton. (2015). Deep learning. *Nature, 521*(7553), 436–444. https://doi.org/10.1038/nature14539
- Michael I. Jordan, & Tom M. Mitchell. (2015). Machine learning: Trends, perspectives, and prospects. *Science, 349*(6245), 255–260. https://doi.org/10.1126/science.aaa8415
- Zhi-Hua Zhou. (2021). *Machine learning*. Springer.
- Shai Shalev-Shwartz, & Shai Ben-David. (2014). *Understanding machine learning: From theory to algorithms*. Cambridge University Press.
- Russell, S., & Norvig, P. (2021). *Artificial intelligence: A modern approach* (4th ed.). Pearson.
- Ramsundar, B., Eastman, P., Walters, P., & Pande, V. (2019). *Deep learning for the life sciences*. O'Reilly Media.
- Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiology and Drug Safety, 18*(6), 427–436. https://doi.org/10.1002/pds.1742
- Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012). Novel data-mining methodologies for adverse drug event discovery and analysis. *Clinical Pharmacology & Therapeutics, 91*(6), 1010–1021. https://doi.org/10.1038/clpt.2012.50
- Sarker, A., Ginn, R., Nikfarjam, A., O'Connor, K., Smith, K., Jayaraman, S., Upadhaya, T., & Gonzalez, G. (2015). Utilizing social media data for pharmacovigilance: A review. *Journal of Biomedical Informatics, 54*, 202–212. https://doi.org/10.1016/j.jbi.2015.02.004
- Xu, R., Wang, Q., & Wang, X. (2014). Mining adverse drug reactions from electronic health records using machine learning. *Artificial Intelligence in Medicine, 61*(1), 1–9.
- Martin, A. (2020). *Martin's physical pharmacy and pharmaceutical sciences* (8th ed.). Wolters Kluwer.
- Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2020). *Handbook of pharmaceutical excipients* (8th ed.). Pharmaceutical Press.
- Niazi, S. K. (2019). *Handbook of pharmaceutical manufacturing formulations* (2nd ed.). CRC Press.
- Sinko, P. J. (2020). *Martin's physical pharmacy and pharmaceutical sciences* (8th ed.). Wolters Kluwer.
- Waller, P., & Evans, S. (2003). A model for the future conduct of pharmacovigilance. *Pharmacoepidemiology and Drug Safety, 12*(1), 17–29. https://doi.org/10.1002/pds.768
- Wisniewski, A. F. Z., Bate, A., Bousquet, C., Brueckner, A., Candore, G., Coloma, P. M., et al. (2022). Good signal detection practices in pharmacovigilance. *Drug Safety, 45*(5), 469–490. https://doi.org/10.1007/s40264-022-01173-1
- Vilar, S., Harpaz, R., Uriarte, E., Santana, L., Rabadan, R., & Friedman, C. (2014). Drug-drug interaction through molecular structure similarity analysis. *Journal of the American Medical Informatics Association, 21*(6), 1066–1074.
- Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in healthcare. *JAMA, 319*(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391
- Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
- Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2020). The emerging evidence of digital health technologies in neurological disorders. *Nature Reviews Neurology, 16*(10), 581–592.
- Cummings, J., Lee, G., Zhong, K., Fonseca, J., & Taghva, K. (2021). Alzheimer's disease drug development pipeline: 2021. *Alzheimer's & Dementia: Translational Research & Clinical Interventions, 7*(1), e12179.
- Cummings, J., Apostolova, L. G., Rabinovici, G. D., et al. (2024). Disease-modifying therapies for Alzheimer's disease. *Nature Reviews Drug Discovery, 23*(2), 87–106.
- International Council for Harmonisation. (2023). *ICH E2E pharmacovigilance planning guideline*. International Council for Harmonisation.
- Organisation for Economic Co-operation and Development. (2024). *OECD framework for*

artificial intelligence governance. OECD Publishing.

 Zhang, L., Tan, J., Han, D., & Zhu, H. (2017). From machine learning to deep learning: Progress in machine intelligence for rational drug discovery. *Drug Discovery Today, 22*(11), 1680–1685. https://doi.org/10.1016/j.drudis.2017.08.010